Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLUDARA vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fludarabine is a purine nucleotide analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to cell death in dividing lymphocytes.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
B-cell chronic lymphocytic leukemia (CLL) in adults who have not responded to or have progressed during treatment with at least one standard alkylating-agent regimen,Off-label: non-Hodgkin lymphoma, acute myeloid leukemia, conditioning for hematopoietic stem cell transplantation
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
25 mg/m^2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Fludarabine phosphate: 0.7-1 h (rapid dephosphorylation). Active metabolite 2-fluoro-ara-A: terminal t1/2 20-30 h (up to 40 h in renal impairment).
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Fludarabine is dephosphorylated in serum to 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A), which is then phosphorylated intracellularly to active triphosphate (F-ara-ATP). Further metabolism involves deamination by adenosine deaminase, but the primary route is renal excretion of unchanged drug and metabolites.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Renal: 60% excreted unchanged in urine; biliary/fecal: <5% as metabolites.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Fludarabine: 19-29% (primarily albumin); 2-fluoro-ara-A: minimal binding.
Approximately 20–30% bound to plasma proteins.
Vd: 2.4 L/kg (fludarabine); 0.5-0.9 L/kg (2-fluoro-ara-A, approximating total body water).
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Oral: 55-75% under fasting conditions; food reduces Cmax but not AUC.
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
Cr Cl 30-70 m L/min: reduce dose by 20%. Cr Cl <30 m L/min: contraindicated.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
No specific recommendations for hepatic impairment; use with caution in severe hepatic impairment (Child-Pugh C).
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Not established for pediatric patients; safety and efficacy not determined.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No specific adjustment; monitor renal function and hematologic parameters closely.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
WARNING: FLUDARA MAY CAUSE SEVERE BONE MARROW SUPPRESSION (ANEMIA, THROMBOCYTOPENIA, NEUTROPENIA) AND MAY INDUCE AUTOIMMUNE HEMOLYTIC ANEMIA. PATIENTS SHOULD BE MONITORED CLOSELY FOR HEMATOLOGIC TOXICITY. NEUROTOXICITY (INCLUDING BLINDNESS, COMA, AND DEATH) HAS BEEN REPORTED, PARTICULARLY AT HIGH DOSES (>40 mg/m2/day).
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Severe bone marrow suppression, particularly thrombocytopenia, anemia, and neutropenia,Autoimmune hemolytic anemia, which can be fatal,Neurotoxicity, especially at high doses; monitor for altered mental status, visual disturbances, seizures,Tumor lysis syndrome, especially in patients with high tumor burden,Immunosuppression and increased risk of opportunistic infections,Pulmonary toxicity including interstitial pneumonitis,Hepatotoxicity and increased liver enzymes,Use with caution in renal impairment; dose adjustment required (Cr Cl <30 m L/min)
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
Hypersensitivity to fludarabine or any component of the formulation,Severe renal impairment (Cr Cl <30 m L/min) unless benefit outweighs risk,Pregnancy (can cause fetal harm),Lactation (discontinue nursing or drug)
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
No specific dietary restrictions. Maintain adequate hydration. Grapefruit juice may interact; avoid excessive consumption. Avoid alcohol due to possible hepatotoxicity.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
Fludarabine is contraindicated in pregnancy. It is a nucleoside analog with known teratogenic and embryotoxic effects. First trimester exposure is associated with major congenital malformations, particularly neural tube defects, craniofacial anomalies, and limb defects. Second and third trimester exposure can cause fetal growth restriction, myelosuppression, and increased risk of fetal death. Both animal studies and human case reports confirm significant fetal harm.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
No data exist on fludarabine excretion into human breast milk. Given its mechanism of action (DNA synthesis inhibitor) and potential for severe adverse effects (e.g., myelosuppression, carcinogenesis) in a nursing infant, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is unknown.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
No established dose adjustments exist for fludarabine during pregnancy. Due to increased plasma volume, renal clearance, and altered pharmacokinetics in pregnancy, standard dosing may result in subtherapeutic levels. However, given the high teratogenic risk, use is contraindicated; if unavoidable (e.g., life-threatening maternal condition), consider therapeutic drug monitoring and dose individualization based on AUC, but data are extremely limited and safety cannot be assured.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
Fludarabine is a purine analog used in B-cell chronic lymphocytic leukemia (CLL). It requires dose adjustment in renal impairment (Cr Cl <30 m L/min). Myelosuppression is dose-limiting; monitor blood counts. Use with caution in patients with prior autoimmune hemolytic anemia. Trimethoprim-sulfamethoxazole should be given for Pneumocystis jirovecii prophylaxis. Allopurinol is recommended for tumor lysis syndrome prevention. Administer IV over 30 minutes or longer.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
Take this medication exactly as prescribed by your doctor.,You will need regular blood tests to monitor your blood cell counts.,Avoid live vaccines during treatment and for 12 months after.,Report any signs of infection (fever, chills, sore throat) or unusual bleeding/bruising immediately.,Use effective contraception during treatment and for at least 6 months after the last dose.,Drink plenty of fluids to help prevent kidney problems.,Avoid exposure to people with infections.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
"Roflumilast, a selective phosphodiesterase-4 (PDE4) inhibitor, enhances intracellular cyclic AMP levels, leading to suppression of pro-inflammatory cytokine production and modulation of immune cell function. Fludarabine, a purine analog used in hematologic malignancies, exerts immunosuppressive effects through inhibition of DNA synthesis and lymphocyte apoptosis. Concurrent use may result in additive or synergistic immunosuppression, increasing the risk of severe infections, including opportunistic infections, and potentially delaying immune recovery in patients already immunocompromised due to fludarabine therapy."
"The combination of tacrolimus and fludarabine may increase the risk of toxicity, particularly nephrotoxicity and neurotoxicity, due to additive immunosuppressive effects and potential pharmacokinetic interactions. Fludarabine may inhibit the metabolism of tacrolimus through CYP3A4 competition, leading to elevated tacrolimus levels and increased adverse effects, including renal impairment and neurological symptoms such as tremors and seizures. Close monitoring is required to avoid severe outcomes like opportunistic infections and organ damage."
"Fludarabine may decrease the cardiotoxic activities of Digitoxin."
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLUDARA vs CLADRIBINE, answered by our medical review team.
FLUDARA is a Antineoplastic Agent that works by Fludarabine is a purine nucleotide analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to cell death in dividing lymphocytes.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLUDARA and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLUDARA is: 25 mg/m^2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLUDARA and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLUDARA is classified as Category C. Fludarabine is contraindicated in pregnancy. It is a nucleoside analog with known teratogenic and embryotoxic effects. First trimester exposure is associated with major congenital . CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.